Literature DB >> 34974123

The role of enteric dysbacteriosis and modulation of gut microbiota in the treatment of inflammatory bowel disease.

Wei Niu1, Fuyan Yang2, Ziwei Fu1, Yuelin Dong1, Zhenhai Zhang3, Jianming Ju4.   

Abstract

The incidence of inflammatory bowel disease (IBD) is globally increasing. This disorder seriously affects the quality of life in patients. Interestingly, studies have detected that the intestinal flora imbalance is a critical factor in the progression of IBD. One potential treatment strategy for IBD involves regulating the composition and function of the intestinal flora. To date, a multitude of experiments have confirmed the relationship between intestinal flora, immune regulation, and anti-inflammation. The intestinal flora can reduce intestinal inflammation by regulating immunity and increasing the secretion of metabolic short-chain fatty acids. In this review, we discuss the composition and function of the intestinal flora, the relationship between the intestinal flora and the host, the role of intestinal flora disorders in IBD, and the progress in IBD treatment. Combining the regulation of the intestinal flora with probiotics treatment is considered a promising strategy for substantially improving the treatment of IBD.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Composition; IBD; Intestinal flora; Modulation

Mesh:

Year:  2021        PMID: 34974123     DOI: 10.1016/j.micpath.2021.105381

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  1 in total

1.  Engineered yeast-based eATP precisely controlled system for the treatment of inflammatory bowel disease.

Authors:  Adnan Hassan Tahir; Yong Tang
Journal:  Purinergic Signal       Date:  2022-01-17       Impact factor: 3.950

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.